Amplia Gets Ethics Approval for Pancreatic Cancer Trial
The ACCENT-Mini trial will test daily-dosed narmafotinib alongside chemotherapy in patients with metastatic pancreatic cancer at three Australian sites.
Updated on Nov. 19, 2026 in Cancer

Amplia Therapeutics has received ethics approval to begin its ACCENT-Mini clinical trial, which tests narmafotinib alongside chemotherapy in metastatic pancreatic cancer patients. Recruitment will take place across three selected Australian clinical trial sites.
Why it matters
Pancreatic cancer remains difficult to treat, and the trial aims to determine whether combining narmafotinib with chemotherapy can improve outcomes. Safety and pharmacokinetic data are intended to support a pivotal FDA study and a possible path toward commercial approval.
The prior ACCENT trial reported a 36 per cent confirmed tumour response rate, a 7.8 per cent complete response rate and median overall survival of 11.1 months. The optimal safe and effective dosing rate for the daily regimen is still to be determined by ACCENT-Mini.
The players
Amplia Therapeutics
Amplia Therapeutics is a biotechnology company developing narmafotinib, a Focal Adhesion Kinase inhibitor being tested in solid tumour cancers.
The details
Narmafotinib blocks Focal Adhesion Kinase, a protein found at high levels in solid tumours, and the drug is designed to reduce the dense fibrotic tissue that surrounds tumours. The ACCENT-Mini trial will recruit patients across three selected Australian clinical trial sites.
Timeline
Ethics approval for ACCENT-Mini was received on 19 November 2026.
Safety and pharmacokinetic data from the trial are expected in late Q1 or early Q2 of 2027.
Research Trajectory
The ACCENT-Mini trial builds directly on the earlier ACCENT trial, which reported a 36 per cent confirmed tumour response rate in metastatic pancreatic cancer. The FDA's recent approval of a KRAS-targeting drug, which showed a significant survival benefit, places the trial within a wider push to improve treatment for this disease.
For patients with metastatic pancreatic cancer, the ACCENT-Mini trial offers a possible new treatment option to test alongside chemotherapy at participating Australian sites. Eligible patients should discuss trial enrolment with their oncology team.
The takeaway
Combining targeted therapies with chemotherapy is being tested as a way to improve results in pancreatic cancer, a disease where KRAS mutations are present in more than 90 per cent of cases. Patients interested in trials should ask their doctor about available options.
What happens next
Safety and pharmacokinetic data from the ACCENT-Mini trial are expected in late Q1 or early Q2 of 2027, and could support the design of a pivotal FDA study.
Further reading
Explore more on Cancer research and treatment developments.
Source note: This article includes information reported by The Sydney Morning Herald.






